TY - JOUR
T1 - Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
T2 - A State-of-the-Art Review
AU - Jiang, David H.
AU - Roy, Darius J.
AU - Gu, Brett J.
AU - Hassett, Leslie C.
AU - McCoy, Rozalina G.
N1 - Funding Information:
This effort was funded by the National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases (grant K23DK114497 [R.G.M.]) and the Mayo Clinic Research Pipeline K2R Program Award (R.G.M.). Study contents are the sole responsibility of the authors and do not necessarily represent the official views of National Institutes of Health. Dr McCoy has received support from the National Institute of Diabetes and Digestive and Kidney Diseases (grants R03DK127010 and P30DK11024) and AARP (Quality Measure Innovation Grant) in the past 36 months. The authors have no relationships relevant to the contents of this paper to disclose.
Funding Information:
The authors thank Andrea M. Li, BSc (Eastern Virginia Medical School), for her assistance in editing the manuscript.
Publisher Copyright:
© 2021 The Authors
PY - 2021/9/1
Y1 - 2021/9/1
N2 - The vast majority of patients (>99%) with severe acute respiratory syndrome coronavirus 2 survive immediate infection but remain at risk for persistent and/or delayed multisystem. This review of published reports through May 31, 2021, found that manifestations of postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) affect between 33% and 98% of coronavirus disease 2019 survivors and comprise a wide range of symptoms and complications in the pulmonary, cardiovascular, neurologic, psychiatric, gastrointestinal, renal, endocrine, and musculoskeletal systems in both adult and pediatric populations. Additional complications are likely to emerge and be identified over time. Although data on PASC risk factors and vulnerable populations are scarce, evidence points to a disproportionate impact on racial/ethnic minorities, older patients, patients with preexisting conditions, and rural residents. Concerted efforts by researchers, health systems, public health agencies, payers, and governments are urgently needed to better understand and mitigate the long-term effects of PASC on individual and population health.
AB - The vast majority of patients (>99%) with severe acute respiratory syndrome coronavirus 2 survive immediate infection but remain at risk for persistent and/or delayed multisystem. This review of published reports through May 31, 2021, found that manifestations of postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) affect between 33% and 98% of coronavirus disease 2019 survivors and comprise a wide range of symptoms and complications in the pulmonary, cardiovascular, neurologic, psychiatric, gastrointestinal, renal, endocrine, and musculoskeletal systems in both adult and pediatric populations. Additional complications are likely to emerge and be identified over time. Although data on PASC risk factors and vulnerable populations are scarce, evidence points to a disproportionate impact on racial/ethnic minorities, older patients, patients with preexisting conditions, and rural residents. Concerted efforts by researchers, health systems, public health agencies, payers, and governments are urgently needed to better understand and mitigate the long-term effects of PASC on individual and population health.
KW - coronavirus disease 2019
KW - disparities
KW - long COVID
KW - postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection
KW - vulnerable population
UR - http://www.scopus.com/inward/record.url?scp=85116424114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116424114&partnerID=8YFLogxK
U2 - 10.1016/j.jacbts.2021.07.002
DO - 10.1016/j.jacbts.2021.07.002
M3 - Review article
AN - SCOPUS:85116424114
SN - 2452-302X
VL - 6
SP - 796
EP - 811
JO - JACC: Basic to Translational Science
JF - JACC: Basic to Translational Science
IS - 9-10
ER -